The description of the new pharmaceutical salts of rosiglitazone was presented.

Rosiglitazone is an oral drug that reduces the glucose level in the blood. It is used for treating patients with type 2 diabetes and is in a class of anti-diabetic drugs called thiazolidinediones.

The possibilities to obtain of rosiglitazone salts with pharmaceutically acceptable organic acids were tested. The conditions of the synthesis for three possible new salts to obtain and also the technology for one of them were worked out.

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/14839 must be provided.

1. The comparison of the stability indicating  two HPLC methods and their application for the determination of bosentan in coated tablets 
2. Elaboration of travoprost eye drops formulation.
3. What modern crystallography can add to pharmaceutical research?
4. Antiproliferative and cytotoxic effect of vitamin D₃ and its derivatives on the selected cells with a higher proliferative potential
5. Improved manufacturing process of bosentan monohydrate.
6. Evaluation of potential genotoxic impurities in prasugrel intermediate by HPLC chromatography
7. Simultaneous CE determination of counterion and possible impurity from synthetic route in pharmaceutical substance prasugrel hydrochloride.
8. Pharmaceutical  technologies  – why do they have to be innovative
9. A novel convergent synthesis of the prostaglandin F_2α analogues
10. An application of accelerator mass spectrometry (AMS) in pediatric clinical studies. Paracetamol, midazolam and spironolactone radiosynthesis and certification.
11. Comparative permeation studies of tacalcitol through the human skin from brand product versus generic product
12. HPLC method for determination of the enantiomeric purity of a new ω chain aldehyde synthon used in the synthesis of travoprost
13. Vitamin D analogs enhance the activity of imatinib mesylate in human non-small cell lung cancer model
14. Colon cancer treatment with the use of vitamin D analogs and irinotecan 
15. Experimental and theoretical charge density studies on a model analogue of vitamin D
16. Synthetic Technologies of Pharmaceutical Substances
17. The influence of (24R)-1,24- dihydroxyvitamin D₃ on the anticancer activity of 5-fluorouracil in human colon cancer model
18. The use of the hyphenated LC-MS/MS technique for the characterisation of impurity profile of Quetiapine during drug development
19. A novel synthesis of 19-nor analogs of vitamin D
20. The influence of novel analogs of vitamin D₃ on the antiproliferative activity of cisplatin or doxorubicin on human promyelocytic leukaemia cell line HL-60 
21. Isolation, structural elucidation and characterization of impurities in latanoprost
22. New calcipotriol analogs, their toxicity and antitumor activity in vivo in comparison to the affinity with VDR and DBP
23. High-yielded method of synthesis of voriconazole.
24. Development of HPLC and GC methods for analysis of Zolmitriptan of pharmaceutical purity
25. Polimorphism of Active Pharmaceutical Ingredients
26. ROPINIROL - GENERIC DRUG FOR PARKINSON'S DISEASE
27. CHARACTERIZATION OF ARIPIPRAZOLE SOLVATE WITH ETHANOL AND POLYMORPHIC FORMS PRODUCED DURING ITS HEATING
28. ANTITUMOR EFFECT OF CISPLATIN OR FLUOROURACIL IN COMBINED TREATMENT WITH (24R)-1,24-DIHYDROXYVITA- MIN D₃
29. COMBINATION OF: IMATINIB, PRI-2191 AND CYTOSTATICS - THE ANTIPROLIFERATIVE EFFECTS ON HL-60 LEUKEMIA CELL LINE
30. ANTIPROLIFERATIVE ACTIVITY IN VITRO OF DIASTEREOMERIC ANALOGUES OF VITAMIN D3 AGAINST NORMAL AND CANCER CELL LINES
31. THE COMPARISON OF TWO VALIDATED HPLC METHODS FOR THE DETERMINATION OF (+)-CLOPIDOGREL HYDROGENSULFATE PURITY WITH THE USP METHOD.